- Nymox Pharmaceutical (NASDAQ:NYMX +0.3%) announces that it expects to file a New Drug Application (NDA) later this year seeking U.S. approval for fexapotide triflutate for the treatment of benign prostate hyperplasia (BPH) or enlarged prostate.
- Fexapotide triflutate (NX-1207) is a pro-apoptotic (promotes cell death) protein administered directly into the prostate via a transrectal injection that does not require anesthesia or sedation.
- The company's marketing application in Europe is currently under EMA review.
- Previously: Nymox Pharma's fexapotide shows long-term benefit in men with low-grade prostate cancer; shares ahead 20% (Jan. 22)
Nymox to file U.S. marketing application for fexapotide triflutate for BPH
Recommended For You
About NYMXF Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
NYMXF | - | - |
Nymox Pharmaceutical Corporation |